In vivo imaging with oligonucleotides for diagnosis and drug development

Gut

Volumn 52, Issue SUPPL. 4, 2003, Pages

  Tavitian, B ^a,b  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CARBON 11; DACARBAZINE; DEOXYRIBONUCLEOSIDE; FLUORINE 18; FOMIVIRSEN; IODINE 125; NITROGEN 13; OBLIMERSEN; OLIGONUCLEOTIDE; OXYGEN 15; PHOSPHOROTHIOIC ACID DERIVATIVE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RNA; TRACER;

CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DRUG DETERMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; GENE EXPRESSION; GENE TARGETING; HUMAN; IN VIVO STUDY; LYMPHOMA; MELANOMA; MOLECULAR BIOLOGY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETINITIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ANALYSIS;

EID: 0038629103     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.suppl_4.iv40     Document Type: Conference Paper

References (112)

1. Jones T. The imaging science of positron emission tomography. Eur J Nuc Med 1996;23:807-13.
2. Aboagye EO, Price PM, Jones T. In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography. Drug Discov Today 2001;6:293-302.
3. Crooke ST, Lebleu B. Antisense research and applications. Boca Raton: CRC Press, 1993:577.
4. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990;346:818-22.
5. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990;249:505-10.
6. Agrawal S. Antisense therapeutics. Totawa: Humana Press, 1996.
7. Beilkova A, Zarytova V, Grineva N. Synthesis of ribonucleosides and diribonucleoside phosphates containing 2-chloro-ethylamine and nitrogen mustard residues. Tetrahedron Lett 1967;8:3557-62.
8. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents: is the bullet really magical? Science 1993;261:1004-12.
9. Agrawal S, Tang JY, Brown DM. Analytical study of phosphorothioate analogues of oligodeoxynucleotides using high-performance liquid chromatography. J Chromatogr 1990;509:396-9.
10. Chen T-L, Miller PS, Tso PO, et al. Disposition and metabolism of oligodeoxynucleoside methylphosphonate following a single iv injection in mice. Drug Metab Dispos 1990;18:815-18.
11. Giles RV, Tidd DM. Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures. Nucleic Acids Res 1992;20:763-70.
12. Iribarren AM, Cicero DO, Neuner PJ. Resistance to degradation by nucleases of (2′S)-2′-deoxy-2′-C-methyloligonucleotides, novel potential antisense probes. Antisense Res Dev 1994;4:95-8.
13. Jorgensen PN, Stein PC, Wengel J. Synthesis of 3′-C-(hydroxymethyl)thymidine - Introduction of a novel class of deoxynucleosides and oligodeoxynucleotides. J Am Chem Soc 1994;116:2231-2.
14. Miller PS. Oligonucleoside methylphosphonates as antisense reagents. BioTechnology 1991;9:358-62.
15. Larrouy B, Blonski C, Boiziau C, et al. RNase H-mediated inhibition of translation by antisense oligodeoxyribonucleotides: use of backbone modification to improve specificity. Gene 1992;121:189-94.
16. Kawosaki AM, Casper MD, Freier SM, et al. Uniformly modified 2′-deoxy-2′-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J Med Chem 1993;36:831-41.
17. Monia BP, Lesnik EA, Gonzalez C, et al. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 1993;268:14514-22.
18. Nielsen PE, Egholm M, Buchardt O. Peptide nucleic acid (PNA) - a DNA mimic with a peptide backbone. Bioconj Chem 1994;5:3-7.
19. Moulds C, Lewis JG, Froehler BC, et al. Site and mechanism of antisense inhibition by C.5 propyne oligonucleotides. Biochemistry 1995;34:5044-53.
20. Agrawal S, Zhang X, Lu Z, et al. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol 1995;50:571-6.
21. Sanghvi YS, Hoke GD, Freier SM, et al. Antisense oligodeoxynucleotides: synthesis, biophysical and biological evaluation of oligodeoxynucleotides containing modified pyrimidines. Nucleic Acids Res 1993;1:3197-203.
22. Stein D, Foster E, Huang SB, et al. A specificity comparison of four antisense types: morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev 1997;7:151-7.
23. Faria M, Spiller DG, Dubertret C, et al. Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo. Nat Biotechnol 2001;19:40-4.
24. Zhao Q, Matson S, Herrera CJ, et al. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev 1993;3:53-66.
25. Tavitian B. In vivo antisense imaging. Q J Nucl Med 200;44:236-55.
26. Younes CK, Boisgard R, Tavitian B. Labelled oligonucleotides as radiopharmaceuticals: pitfalls, problems and perspectives. Curr Pharm Des 2002;8:1451-66.
27. Wilbur DS, Hadley SW, Hylarides MD, et al. Development of a stable radioiodinating reagant to label monoclonal antibodies for radiotherapy of cancer. J Nucl Med 1989;30:216-26.
28. 18F for in vivo PET imaging. J Label Compounds Radiopharm 1997;39:319-30.
29. Kühnast B, Dollé F, Terrazzino S, et al. A general method to label antisense oligonucleotides with radioactive halogens for pharmacological and imaging studies. Bioconj Chem 2000;11:627-36.
30. Kühnast B, Dollé F, Vaufrey F, et al. Fluorine-18 labeling of oligonucleotides bearing chemically - modified ribose · phosphate backbones. J Label Compounds Radiopharm 2000;43:837-48.
31. Kuhnast B, Dollé F, Tavitian B. Fluorine-18 labeling of peptide nucleic acids. J Label Compounds Radiopharm 2002;45:1-11.
32. DeLong RK, Nohing A, Fisher M, et al. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice. Antisense Nucleic Acid Drug Dev 1997;7:71-7.
33. Deverre JR, Boutet V, Boquet, et al. A competitive enzyme hybridization assay for plasma determination of phosphodiester and phosphorothioate antisense oligonucleotide. Nucleic Acids Res 1997;25:3584-9.
34. Tavitian B, Terrazzino S, Kühnast B, et al. In vivo imaging of oligonucleotides with positron emission tomography. Nat Med 1998;4:467-71.
35. Zhang YM, Wang Y, Liu N, et al. In vitro investigations of tumor targeting with (99m)Tc-labeled antisense DNA. J Nucl Med 2001;42:1660-9.
36. Zhang YM, Liu N, Zhu ZH, et al. Influence of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled to antisense DNA. Eur J Nucl Med 2000;27:1700-7.
37. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 1978;75:285-8.
38. Hnatowich DJ. Changing focus: applying antisense to nuclear medicine imaging. Mol Med Today 1999;5:151.
39. Akhtar S, Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharmacol Sci 1997;18:12-18.
40. Wickstrom E. Clinical trials of genetic therapy with antisense DNA and DNA vectors, New York: Marcel Decker, 1998.
41. Hogrefe RI. An antisense oligonucleotide primer. Antisense Nucleic Acid Drug Dev 1999;9:351-7.
42. http://www.trilinkbiotech.com/newsite/Technical_Info/ Articles/pdfs/antisense_oligo_primer.pdf
43. Agarwal N, Gewirtz AM. Oligonucleotide therapeutics for hematologic disorders. Biochim Biophys Acta 1999;1489:85-96.
44. de Fabritiis P, Petti MC, Montefusco E, et al. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 1998;91:3156-62.
45. Ratajczak MZ, Kant JA, Luger SM, et al. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 1992;89:11823-7.
46. Bishop MR, Iversen PL, Bayever E, et al. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 1996;14:1320-6.
47. Ratajczak MZ, Hijiya N, Catani L, et al. Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. Blood 1992;79:1956-61.
48. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151-7.
49. Cotter FE, Johnson P, Hal, P, et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 1994;9:3049-55.
50. Jansen B, Schlagbauer-Wadl H, Brown BD, et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998;4:232-4.
51. Jansen B, Wacheck V, Heere-Ress E, et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000;356:1728-33.
52. Andrews DW, Resnicoff M, Flanders AE, et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 2001;19:2189-200.
53. Crooke ST. Evaluating the mechanism of action of antiproliferative antisense drugs. Antisense Nucleic Acid Drug Dev 2000;10:123-7.
54. Sethi S, Lipford G, Wagner H, et al. Postexposure prophylaxis against prian disease with a stimulator of innate immunity. Lancet 2002;360:229-30.
55. Piwnica Worms D. Making sense out of anti-sense: challenges of imaging gene translation with radiolabeled oligonucleotides. J Nucl Med 1994;35:1064-6.
56. Stein CA. Keeping the biotechnology of antisense in context. Nature Biotech 1999;17:209.
57. Kedzierski W, Porter JC. Quantitative study of tyrosine hydroxylase mRNA in catecholaminergic neurons and adrenals during develoipment and aging. Mol Brain Res 1990;7:45-51.
58. Srinivasan SK, Tewary HK, Iversen PL. Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res Dev 1995;5:131-9.
59. Benimetskaya L, Tonkinson JL, Koziolkiewicz M, et al. Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P- chirality independent. Nucleic Acids Res 1995;23:4239-45.
60. Hawley P, Gibson I. Interaction of oligodeoxynucleotides with mammalian cells. Antisense Nucleic Acid Drug Dev 1996;6:185-95.
61. Henry SP, Novotny W, Leeds J, et al. Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev 1997;7:503-10.
62. Yakubov LA, Deeva EA, Zarytova VF, et al. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc Natl Acad Sci USA 1989;86:6454-8.
63. Geselowitz DA, Neckers LM. Analysis of oligonucleotide binding, internalization, and intracellular trafficking utilizing a novel radiolabeled crosslinker. Antisense Res Dev 1992;2:17-25.
64. Geselowitz DA, Neckers LM. Bovine serum albumin is a major oligonucleotide-binding protein found on the surface of cultured cells. Antisense Res Dev 1995;5:213-17.
65. Srinivasan SK, Tewary HK, Iversen PL. Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res Dev 1995;5:131-9.
66. Derossi D, Chassaing G, Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol 1998;8:84-7.
67. Stein CA. Phosphorothioate antisense oligodeoxynudeotides: questions of specificity. Trends Biotechnol 1996;14:147-9.
68. Prochiantz A. Peptide nucleic acid smugglers. Nat Biotechnol 1998;16:819-20.
69. Feigner PL, Barenholz Y, Behr JP, et al. Nomenclature for synthetic gene delivery systems. Hum Gene Ther 1997;8:511-12.
70. Lavigne C, Thierry AR. Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system. Biochem Biophys Res Commun 1997;237:566-71.
71. Tavitian B, Marzabal S, Boutet V, et al. Characterization of a synthetic anionic vector for oligonudeotide delivery using in vivo whole body dynamic imaging. Pharm Res 2002;19:367-76.
72. Osborne SE, Ellington AD. Nucleic acid selection and the challenge of combinatorial chemistry. Chem Rev 1997;97:349-70.
73. Eaton BE. The joys of in vitro selection: chemically dressing oligonucleotides to satiate protein targets. Curr Opin Chem Biol 1997;1:10-16.
74. Wilson DS, Szostak JW. In vitro selection of functional nucleic acids. Annu Rev Biochem 1999;68:611-47.
75. Brody EN, Gold, L. Aptamers as therapeutic and diagnostic agents. J Biotechnol 2000;74:5-13.
76. Hesselberth J, Robertson MP, Jhaveri S, et al. In vitro selection of nucleic acids for diagnostic applications. J Biotechnol 2000;74:15-25.
77. Jhaveri S, Rajendran M, Ellington AD. In vitro selection of signaling aptamers. Nat Biotechnol 2000 18:1293-7.
78. Hicke BJ, Stephens AW. Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest 2000;106:923-8.
79. Blank M, Weinschenk T, Priemer M, et al. Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels, selective targeting of endothelial regulatory protein pigpen. J Biol Chem 2001;276:16464-8.
80. Usman N, Blatt LM. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J Clin Invest 2000;106:1197-202.
81. Aurup H, Williams DM, Eckstein F. 2′-Fluoro- and 2′-amino-2′-deoxynucleoside 5′-triphosphates as substrates for T7 RNA polymerase. Biochemistry 1992;31:9636-41.
82. Ruckman J, Green LS, Beeson J, et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998;273:2055-67.
83. Wlotzka B, Leva S, Eschgfaller B, et al. In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc Natl Acad Sci USA 2002;99:8898-902.
84. Gold L, Polisky B, Uhlenbeck O, et al. Diversity of oligonucleotide functions. Ann Rev Biochem 1995;64:763-97.
85. Osborne SE, Matsumura I, Ellington AD. Aptamers as therapeutic and diagnostic reagents: problems and prospects. Curr Opin Chem Biol 1997;1:5-9.
86. Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 1999;45:1628-50.
87. Famulok M, Jenne A. Oligonucleotide libraries-variatio delectat. Curr Opin Chem Biol 1998;2:320-7.
88. Gold L. Oligonucleotides as research, diagnostic, and therapeutic agents. J Biol Chem 1995;270:13581-4.
89. White RR, Sullenger BA, Rusconi CP. Developing aptamers into therapeutics. J Clin Invest 2000;106:929-34.
90. Conrad R, Keranen LM, Ellington AD, et al. Isozyme-specific inhibition of protein kinase C by RNA aptamers. J Biol Chem 1994;269:32051-4.
91. Kimoto M, Shirouzu M, Mizutani S, et al. Anti-(Raft-1) RNA aptamers that inhibit Ras-induced Raft-1 activation. Eur J Biochem 2002;269:697-704.
92. Bianchini M, Radrizzani M, Brocardo MG, et al. Specific oligobodies against ERK-2 that recognize both the native and the denatured state of the protein. J Immunol Methods 2001;252:191-7.
93. Morris KN, Jensen KB, Julin CM, et al. High affinity ligands from in vitro selection: complex targets. Proc Natl Acad Sci USA 1998;95:2902-7.
94. Hicke BJ, Marion C, Chang YF, et al. Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem 2001;276:48644-54.
95. Floege J, Ostendorf T, Janssen U, et al. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am J Pathol 1999;154:169-79.
96. Doudna JA, Cech TR, Sullenger BA. Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. Proc Natl Acad Sci USA 1995;92:2355-9.
97. Ostendorf T, Kunter U, Grone HJ, et al. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2001;12:909-18.
98. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61:2929-34.
99. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151-7.
100. Sun S. Technology evaluation: SELEX, Gilead Sciences Inc. Curr Opin Mol Ther 2000;2:100-5.
101. Charlton J, Sennello J, Smith D. In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem Biol 1997;4:809-16.
102. Willis MC, Collins BD, Zhang T, et al. Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug Chem 1998;9:573-82.
103. Hélène C. The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides. Anticancer Drug Res 1991;6:569-84.
104. Panyutin IG, Winters TA, Feinendegen LE, et al. Development of DNA-based radiopharmaceuticals carrying Auger-electron emitters for anti-gene radiotherapy. Q J Nucl Med 2000;44:256-67.
105. Sedelnikova OA, Karamychev VN, Panyutin IG, et al. Sequence-specific gene cleavage in intact mammalian cells by 1251-labeled triplex-forming oligonudeotides conjugated with nuclear localization signal peptide. Antisense Nucleic Acid Drug Dev 2002;12:43-9.
106. Tuschl T. RNA interference and small interfering RNAs. Chembiochem 2001;2:239-45
107. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001;15:188-200.
108. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8.
109. Lee NS, Dohjima T, Bauer G, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002;20:500-5.
110. Paul CP, Good PD, Winer I, et al. Effective expression of small interfering RNA in human cells. Nat Biotechnol 2002;20:505-8.
111. McCaffrey AP, Meuse L, Pham TT, et al. RNA interference in adult mice. Nature 2002;418:38-9.
112. Lewis DL, Hagstrom JE, Loomis AG, et al. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 2002;32:107-8.